Biotech startup with research base in Aarhus raises DKK 75 million

Belgian-Danish biotech company Spica Therapeutics has secured a DKK 75 million seed investment from Bioqube Ventures, Flanders Future Tech Fund and Qbic, among others. The funds will be used to further develop a new type of antibody therapy that targets specific macrophages that play a key role in cancer and fibroinflammatory diseases. Spica Therapeutics announced this in a press release.

Spica is headquartered in Antwerp, but also has a research unit in Aarhus, where parts of the company’s technology and scientific foundation are developed. This applies in particular to the work with so-called functional macrophage fingerprinting technology, which enables selective control of disease-driving cells in the immune system.

“We are thrilled to have the backing of such a strong consortium of investors and collaborators who share our vision of transforming patient care through innovative, macrophage-targeted therapies,” said James Rush, CEO of Spica Therapeutics.

The first programs that are now receiving funding to enter early IND preparatory studies are based on groundbreaking research from Aarhus University, University of Southern Denmark and French INSERM, among others.

The goal of Spica is to create new therapies to address unmet needs, particularly in oncology and autoimmune diseases, where existing therapies are often inadequate or have limited precision.

As part of the investment round, Spica is also entering into a strategic collaboration with Vrije Universiteit Brussel and research institute VIB, providing expertise in imaging and immunobiology.

Indlægget Biotech startup with research base in Aarhus raises DKK 75 million blev først udgivet på TechSavvy.